ValuentumAd

Official PayPal Seal

Johnson & Johnson Issues Fourth Quarter Results

publication date: Jan 24, 2025
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
A graph of financial highlights Description automatically generated
Image Source: J&J. 

For the full year 2024, J&J's free cash flow came in at ~$19.8 billion, up from $18.2 billion last year. The company ended the quarter with ~$12 billion in net debt. J&J made significant pipeline progress in the quarter including RYBREVANT + LAZCLUZE overall survival data, initiation of TAR-200 submission, and the approval of investigational device exemption for its general surgery robotic system, OTTAVA. J&J issued guidance or 2025 calling for operational sales growth of 2.5%-3.5%, below the consensus forecast, and adjusted operational earnings per share growth of $10.75-$10.95, reflecting 8.7% growth at the midpoint. We like J&J, but the company does not make the cut for inclusion in any newsletter portfolio at this time.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.